Glycos Biotechnologies and Solix BioSystems Achieve Positive Results for the Suitability of Solix’s Algal Oils for the Production of Bio-derived Sustainable Chemicals

Share Article

Algal oils proven as next generation feedstock for industrial bacterial fermentation.

Glycos Biotechnologies, Inc. (GlycosBio), an international biochemical company commercializing high-value bio-chemicals, and Solix BioSystems, Inc. (Solix), a leading provider of integrated solutions and services that enable large scale cultivation of algae, today announced their early stage research and development collaboration has yielded positive results. These preliminary experiments demonstrated the potential for Solix’s algae oil to be converted into a range of valuable specialty chemicals through GlycosBio’s suite of proprietary biocatalysts. GlycosBio has a specific interest in synthetic rubber intermediates including bio-derived isoprene.

Solix’s crude algal oil was found to be non-toxic and easily metabolized and upgraded by GlycosBio’s proprietary biocatalysts. Based on the successful production of ethanol from the oil, additional studies are planned to convert the oil to other higher value chemicals. The tests were conducted at GlycosBio’s research facilities in Houston and led by Dr. Daniel J. Monticello, the company’s Vice President of Research and Development.

“Upgrading sustainable, non-food, renewable carbon sources like Solix’s algal oil is a central element of GlycosBio’s feedstock diversity and technology strategy,” said Dr. Monticello. “It appears the potential range of chemical intermediate products that can be produced from this algal oil is vast. Converting next generation feedstocks, such as algae-derived fatty acids, is a key dimension of GlycosBio’s long term value creation plan and aligns well with our near term commercial projects in Asia, North America and Europe. More broadly this class of feedstock is important for the entire industry.”

“This successful proof-of concept that Solix’s algae oil can be converted to chemicals represents a milestone in the demonstration of the potential of algae to be a feedstock for a broad range of products beyond fuel,” said Joel Butler, Chief Executive Officer of Solix BioSystems. “These experiments represent an important step towards driving the commercialization of our AGS™ algae production technology for the production of high-value products.”

About Glycos Biotechnologies, Inc.
Glycos Biotechnologies, Inc. (“GlycosBio”) is an international biochemical company commercializing advanced metabolic engineering and microbial strain processes that convert multiple low value feedstocks into a range of high value sustainable chemicals. By designing a portfolio of differentiated microorganisms, GlycosBio’s bioconversion technology produces a diverse set of chemicals, including substitutes for fossil fuel derived petrochemicals, meeting the growing global demand for clean, environmentally safe biochemicals.
GlycosBio is privately held and focused on biochemical commercialization and production with established global partnerships including relationships with petrochemical companies to secure low cost, non-petroleum based chemicals. For more information, visit

About Solix BioSystems
Solix BioSystems, Inc. is a developer of algae production technology designed to generate algal biocrude and other algal products on an industrial scale. Its proprietary AGS offers the ability to cost effectively produce algae products with high productivity and reliability. Solix works with partners interested in utilizing its AGS technology to produce products derived from algae and to reduce CO2 emissions. It also sells the Lumian AGS4000, a fully integrated system for outdoor R&D algae cultivation. Solix BioSystems is headquartered in Ft. Collins, Colorado and has a demonstration plant in Southwestern Colorado. The Company is venture funded. For more information, visit

GlycosBio Media Contact:
Lisa Regan
Atingo Public Relations
(713) 252-1791

Solix Biosystems Media Contact:
Joanna Money
VP Business Development
Solix BioSystems
(970) 692 5611


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Lisa Regan
Atingo Public Relations
(713) 252-1791
Email >
Visit website